Verismo Therapeutics Named One of Philadelphia Business Journal's 2025 Best Places to Work for Third Consecutive Year

PHILADELPHIA, July 29, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced it has been named one of the Philadelphia Business Journal's 2025 Best Places to Work, marking the third consecutive year the company has received this recognition.

The award honors companies that excel in creating a positive, engaging workplace culture, based on confidential employee feedback and satisfaction metrics. This continued recognition underscores Verismo's dedication to attracting top talent, fostering a culture of excellence, and enabling its team to deliver transformative therapies for cancer patients with urgent, unmet needs.

"Being recognized for the third year in a row is a reflection of the team-first culture we've worked to cultivate," said Bryan Kim, CEO and co-founder of Verismo Therapeutics. "We're proud to have created an environment where people are driven by purpose and supported in following their passion to help patients."

About Verismo Therapeutics

Verismo Therapeutics, a subsidiary of HLB Innovation, is a pioneer in multi-chain KIR-CAR technology, with assets SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve T cell functional persistence and reduce exhaustion, resulting in improved efficacy against challenging tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. For more information, visit: www.verismotherapeutics.com

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain CAR T cell therapy that has shown highly effective prolonged solid tumor treatment in otherwise CAR-resistant preclinical animal models with challenging tumor microenvironments.  Using NK cell derived KIR and DAP12 split signaling provides a novel paired activation and co-stimulation separate from the usual T cell stimulation pathways. KIR-CAR enables sustained chimeric receptor expression with improved long-term CAR T cell function and decreased T cell exhaustion. This results in CAR T cell resistance to tumor immunosuppression, prolonged functional persistence and improved tumor elimination. Together, this platform provides the potential for improving CAR T treatment in both solid and hematologic tumors.

Forward Looking Statements

This press release contains forward-looking statements, including, but are not limited to, those statements regarding our expectations for the timing, progress, and results of clinical trials; potential regulatory approvals; anticipated benefits, safety, and efficacy of our product candidates; our product development strategies; and other statements that are not historical facts. These forward-looking statements are based on our current expectations and are subject to numerous risks and uncertainties that could cause actual outcomes to differ materially. Important factors that could cause actual results to differ include, among others, risks related to clinical trials, regulatory processes, market acceptance, financial projections, and our ability to successfully develop and commercialize our product candidates. Forward-looking statements in this release represent our beliefs and assumptions only as of the date hereof, and we expressly disclaim any obligation to update these statements as new information becomes available, except as required by law.

Media Contact:
Verismo Therapeutics
Pavel Aprelev, Ph.D.
[email protected]

SOURCE Verismo Therapeutics